Clinical pharmacology in adolescent transgender medicine
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.16213 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Lauren R Cirrincione und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Washington, Seattle, WA, USA. Hauptthemen laut MEDLINE: Transgender Persons, Gonadotropin-Releasing Hormone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Adolescent transgender medicine is a growing clinical field. Gender‐affirming medications for transgender youth may include gonadotropin‐releasing hormone (GnRH) agonists, gender‐affirming hormones or both. To evaluate the potential effects of GnRH agonists (puberty suppression) on pharmacokinetic processes for transgender youth, we searched PubMed from inception to May 2024 for publications on the effects of GnRH agonists on drug absorption, distribution, metabolism or excretion for transgender adolescents or effects on hormones (including gonadotropins, adrenal androgens, sex steroids) that are associated with changes in drug metabolism during puberty in the general adolescent population. No publications discussed the effects of GnRH agonist treatment on pharmacokinetic processes for adolescent transgender people. Sixteen publications observed marked decreases in gonadotropins and sex steroids for both adolescent transgender men and adolescent transgender women and slight effects on adrenal androgens. During GnRH agonist treatment, changes in body composition and body shape were greater for adolescent transgender people than for cisgender adolescent people. Further research is needed to better understand the effects of GnRH agonists on drug metabolism and other pharmacokinetic processes for transgender adolescents receiving GnRH agonists and other gender‐affirming medications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of Washington, Seattle, WA, USA.
- School of Medicine, University of California San Francisco, San Francisco, CA, USA.
- Seattle Children's Hospital, Seattle, WA, USA.
- Department of Pediatrics, University of Washington, Seattle, WA, USA.
ORCID-Profile: Lauren R Cirrincione
Förderung
- NIGMS NIH HHS
- NIH HHS
- National Institute of General Medical Sciences
- National Institutes of Health
Zitieren
APA
Cirrincione, L. R., Huang, K. J., & Sequeira, G. M. (2024). Clinical pharmacology in adolescent transgender medicine. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16213
Vancouver
Cirrincione LR, Huang KJ, Sequeira GM. Clinical pharmacology in adolescent transgender medicine. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16213
BibTeX
@article{Cirrincione2024,
author = {Cirrincione, Lauren R and Huang, Kai J and Sequeira, Gina M},
title = {Clinical pharmacology in adolescent transgender medicine},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.16213}
}
EUVIMED